Kaneko Y, Rowley J D, Variakojis D, Haren J M, Ueshima Y, Daly K, Kluskens L F
Int J Cancer. 1983 Dec 15;32(6):683-92. doi: 10.1002/ijc.2910320606.
Clonal chromosome abnormalities were observed in 30 patients with non-Hodgkin's lymphoma; the type of lymphoma was characterized on the basis of the International Working Formulation. The 30 patients were classified into five groups according to the chromosome abnormality. There were 8 patients with t(14;18), 3 with t(8;14), 7 with a translocation to the long arm of chromosome 3 (a 3q+ chromosome), 5 with near-tetraploidy, and 7 with other abnormalities. Among the 8 patients with t(14;18), 5 had follicular small cleaved-cell lymphoma (FSC), I had follicular mixed cell lymphoma (FM), and 2 had diffuse large-cell lymphoma (DL); the diagnosis in these 2 patients was based on extranodal tissue. All 3 patients with t(8;14) had DL and B-cell markers. Except for 1 patient, all those with a 3q+ chromosome had DL; 4 of those who were tested had B-cell or pre-B-cell markers. Four of the 5 patients with near-tetraploidy had follicular mixed-cell lymphoma, and 2 of the 7 patients with other abnormalities had T-cell lymphoma. Thus, patients with a t(8;14), a 14q+ chromosome, or a 3q+ chromosome all tend to have diffuse large-cell lymphoma, usually of the non-cleaved type. On the other hand, our data suggest that patients with FSC generally have a t(14;18) whereas those with follicular and diffuse mixed small cleaved cells and large noncleaved cells have a different pattern with modal chromosome numbers in the tetraploid range. We added 17 previously reported patients to the 30 presented here and correlated the karyotype with survival. The 6 patients with near-tetraploidy had the longest median survival, 69 months, the 15 patients with t(14;18) had the next longest, 48 months. The 4 patients with t(8;14) had the shortest survival, 12 months, and the 9 with other abnormalities had the next shortest, 17 months. Intermediate survivals of 27 and 30 months were observed in patients with a 14q+ or a 3q+ chromosome, respectively. The median survival of these various categories differs and our data, thus, indicate that the karyotypic pattern of the malignant cell may be a significant independent prognostic feature influencing the survival of patients with non-Hodgkin's lymphoma.
在30例非霍奇金淋巴瘤患者中观察到克隆性染色体异常；根据国际工作分类法对淋巴瘤类型进行了特征描述。根据染色体异常情况将这30例患者分为五组。有8例患者存在t(14;18)，3例存在t(8;14)，7例存在3号染色体长臂易位（一条3q+染色体），5例为近四倍体，7例存在其他异常。在8例t(14;18)患者中，5例患有滤泡性小裂细胞淋巴瘤（FSC），1例患有滤泡性混合细胞淋巴瘤（FM），2例患有弥漫性大细胞淋巴瘤（DL）；这2例患者的诊断基于结外组织。所有3例t(8;14)患者均患有DL且具有B细胞标志物。除1例患者外，所有具有3q+染色体的患者均患有DL；接受检测的患者中有4例具有B细胞或前B细胞标志物。5例近四倍体患者中有4例患有滤泡性混合细胞淋巴瘤，7例其他异常患者中有2例患有T细胞淋巴瘤。因此，存在t(8;14)、14q+染色体或3q+染色体的患者往往患有弥漫性大细胞淋巴瘤，通常为非裂细胞型。另一方面，我们的数据表明，FSC患者通常存在t(14;18)，而那些具有滤泡性和弥漫性混合小裂细胞及大非裂细胞的患者具有不同的模式，其众数染色体数在四倍体范围内。我们将17例先前报告的患者加入到这里呈现的30例患者中，并将核型与生存情况进行关联。6例近四倍体患者的中位生存期最长，为69个月，15例t(14;18)患者的生存期次之，为48个月。4例t(8;14)患者的生存期最短，为12个月，9例其他异常患者的生存期次之，为17个月。14q+或3q+染色体患者的中位生存期分别为27个月和30个月。这些不同类别的中位生存期不同，因此我们的数据表明，恶性细胞的核型模式可能是影响非霍奇金淋巴瘤患者生存的一个重要独立预后特征。
